More on CYTR

- Summary
- Chart
- Profile
- Historical


- Earnings
- Ratings
- Holders


Income Statement
Balance Sheet
Cash Flow Statement


- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks

CYTR Balance Sheet

Click line-items for a historical chart and %
Current assets:
Cash and cash equivalents 11.48M
Marketable securities 27.08M
Proceeds from sale of RXi, received January 6, 2011
Receivable 117.53K
Investment in Adventrx Pharmaceuticals, at market
Income taxes recoverable
Interest receivable 8.46K
Prepaid expenses and other current assets 2.33M
Total current assets 41.02M
Equipment and furnishings, net 175.45K
Goodwill 183.78K
Other assets 117K
Total assets 41.5M
Current liabilities:
Accounts payable 3.85M
Accrued expenses and other current liabilities 2.8M
Warrant liabilities 24.18M
Total current liabilities 30.84M
Stockholders' equity:
Preferred Stock, $.01 par value, 5,000,000 shares authorized, including 15,000 shares of Series A Junior Participating Preferred Stock; no shares issued and outstanding 0
Common stock, $.001 par value, 175,000,000 shares authorized; 109,857,885 and 109,840,445 shares issued and outstanding at June 30, 2011 and December 31, 2010, respectively 42.12K
Additional paid-in capital 289.43M
Accumulated comprehensive income, net of tax
Treasury stock, at cost (633,816 shares) -2.42M
Accumulated deficit -276.39M
Total stockholders' equity 10.66M
Total liabilities and stockholders' equity 41.5M